|
US3498989A
(en)
|
1969-04-16 |
1970-03-03 |
American Home Prod |
Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
|
|
US3870715A
(en)
|
1972-03-09 |
1975-03-11 |
Nikolaus R Hansl |
Substituted amino ethyl meta benzoic acid esters
|
|
US4041174A
(en)
|
1974-08-16 |
1977-08-09 |
Rom-Amer Pharmaceuticals, Ltd. |
Method of treating depression
|
|
US4731379A
(en)
*
|
1983-12-07 |
1988-03-15 |
H.S.C. Corporation |
Flea eradicator
|
|
US5204356A
(en)
|
1985-07-24 |
1993-04-20 |
Glaxo Group Limited |
Treatment of anxiety
|
|
US6150354A
(en)
|
1987-01-15 |
2000-11-21 |
Bonnie Davis |
Compounds for the treatment of Alzheimer's disease
|
|
GB8819494D0
(en)
|
1988-08-16 |
1988-09-21 |
Ucb Sa |
Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
|
|
CA2058455A1
(en)
*
|
1990-12-21 |
1992-06-22 |
Mark W. Collison |
Synergistic effect of lantibiotics in combination with selected agents against gram positive bacteria
|
|
CA2104594C
(en)
*
|
1991-02-22 |
2004-05-11 |
Howard K. Shapiro |
Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
|
|
US6746678B1
(en)
|
1991-02-22 |
2004-06-08 |
Howard K. Shapiro |
Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
|
|
FR2700117B1
(fr)
|
1993-01-07 |
1995-02-03 |
Rhone Poulenc Rorer Sa |
Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
|
|
DE4340273A1
(de)
|
1993-11-26 |
1995-06-01 |
Karla Dr Lehmann |
Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
|
|
US5441981A
(en)
*
|
1994-01-27 |
1995-08-15 |
Buckman Laboratories International, Inc. |
Synergistic antimicrobial compositions containing a halogenated acetophenone and an organic acid
|
|
US5453425A
(en)
|
1994-07-11 |
1995-09-26 |
Janssen Pharmaceutica N.V. |
Risperidone oral formulation
|
|
US6146847A
(en)
*
|
1996-11-01 |
2000-11-14 |
Genespan Corporation |
Stabilized transient gene expression
|
|
DE19925425A1
(de)
*
|
1999-06-02 |
2000-12-07 |
Wessollek Heimo |
Mittel zur Entkeimung bzw. keimreduzierenden Gestaltung von Reinigungs-, Sanitär- und Toilettenartikeln sowie kosmetischen Artikeln, Körperpflegeartikeln und dergleichen verkeimungsgefährdeten Gegenständen
|
|
AU4517201A
(en)
|
1999-12-08 |
2001-06-18 |
Vanderbilt University |
Modulation of in vivo glutamine and glycine levels in the treatment of autism
|
|
WO2002014286A1
(en)
|
2000-08-14 |
2002-02-21 |
Teva Pharmaceutical Industries Ltd. |
Preparation of risperidone
|
|
US20030185754A1
(en)
|
2001-01-16 |
2003-10-02 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
|
EA006654B1
(ru)
|
2001-01-16 |
2006-02-24 |
Женсет С. А. |
Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы
|
|
US7927613B2
(en)
*
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
|
US20100311701A1
(en)
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
|
US20070053976A1
(en)
|
2002-05-17 |
2007-03-08 |
Eisai R & D Management Co., Ltd. |
Novel combination of drugs as antidepressant
|
|
US7053122B2
(en)
|
2002-08-09 |
2006-05-30 |
Pfizer Inc |
Therapeutic use of aryl amino acid derivatives
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
WO2004037234A2
(en)
|
2002-10-24 |
2004-05-06 |
Merz Pharma Gmbh & Co. Kgaa |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
|
CA2798615A1
(en)
*
|
2003-01-21 |
2004-08-05 |
Aptuit (West Lafayette), Llc |
Novel cocrystallization of hydrochloric acid salt of an active agent
|
|
US7452555B2
(en)
|
2003-01-21 |
2008-11-18 |
S.S.C.I., Inc. |
Cocrystallization
|
|
WO2004065348A1
(en)
|
2003-01-23 |
2004-08-05 |
Pfizer Products Inc. |
Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
|
|
JP2006526635A
(ja)
|
2003-06-02 |
2006-11-24 |
サマリタン，ファーマスーティカルス，インク． |
血清中コルチゾール量を調節する方法および組成物
|
|
BRPI0417910A
(pt)
|
2003-12-29 |
2007-04-10 |
Sepracor Inc |
composto ou um sal ou salvato farmaceuticamente aceitáveis do mesmo, e, uso de um composto
|
|
EP1709053B1
(en)
|
2004-01-27 |
2011-04-06 |
Synthon B.V. |
Stable salts of olanzapine
|
|
US20050267176A1
(en)
|
2004-02-18 |
2005-12-01 |
Sepracor Inc. |
Dopamine-agonist combination therapy for improving sleep quality
|
|
CA2565159A1
(en)
|
2004-05-06 |
2005-12-15 |
Cydex, Inc. |
Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
|
|
WO2006007448A2
(en)
|
2004-06-17 |
2006-01-19 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions and related methods of use
|
|
WO2006096439A2
(en)
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
|
CA2505808A1
(en)
*
|
2005-05-02 |
2006-11-02 |
Julie Danielle Globus |
Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans
|
|
WO2006129160A2
(en)
|
2005-06-01 |
2006-12-07 |
Aurobindo Pharma Limited |
Stable aqueous oral solution of risperidone
|
|
US20110045065A1
(en)
|
2005-07-11 |
2011-02-24 |
Ashok Vasantray Vyas |
Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
|
|
US7811604B1
(en)
|
2005-11-14 |
2010-10-12 |
Barr Laboratories, Inc. |
Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
|
|
GB0603181D0
(en)
|
2006-02-17 |
2006-03-29 |
Merck Sharp & Dohme |
Treatment of neurodegenerative and psychiatric diseases
|
|
US20080045547A1
(en)
*
|
2006-07-07 |
2008-02-21 |
Lippa Arnold S |
Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use
|
|
US20080045512A1
(en)
|
2006-08-09 |
2008-02-21 |
Pfizer Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
|
|
WO2008034087A2
(en)
|
2006-09-15 |
2008-03-20 |
Xenoport, Inc. |
Treating schizophrenia with combinations of levodopa and an antipsychotic agent
|
|
EP2167043A4
(en)
*
|
2007-06-06 |
2013-05-01 |
Univ South Florida |
NEW USE CO-CRYSTAL COMPOSITIONS
|
|
US8071143B2
(en)
*
|
2008-04-02 |
2011-12-06 |
Brandeis University |
Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
|
|
US20130338199A1
(en)
|
2008-07-11 |
2013-12-19 |
Uday Saxena |
Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
|
|
GB0813709D0
(en)
|
2008-07-26 |
2008-09-03 |
Univ Dundee |
Method and product
|
|
WO2010027921A1
(en)
*
|
2008-09-03 |
2010-03-11 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
|
JP2010106001A
(ja)
*
|
2008-10-31 |
2010-05-13 |
Theravalues Corp |
Ｐｐａｒ活性化剤
|
|
EP3006024B1
(en)
*
|
2009-01-20 |
2019-03-20 |
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center |
Benzoic acid or salts thereof to enhance the activity of a neuropharmaceutical
|
|
DK3656765T3
(da)
|
2010-07-23 |
2021-06-14 |
Gruenenthal Gmbh |
Salte eller co-krystaller af 3-(3-dimethylamin-1-ethyl-2-methyl-propyl)-phenol
|
|
JP2014508814A
(ja)
|
2011-03-24 |
2014-04-10 |
ユニバーシティ・オブ・サウス・フロリダ |
リチウム組成物
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
PH12012000132B1
(en)
*
|
2011-06-09 |
2014-10-20 |
Servier Lab |
New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
|
|
US9120766B2
(en)
*
|
2011-10-21 |
2015-09-01 |
Amri Ssci, Llc |
Methods of making cocrystals
|
|
JP6205406B2
(ja)
*
|
2012-03-30 |
2017-09-27 |
ナフォーミックス リミテッド |
トラニラスト組成物および共結晶
|
|
ES2910003T3
(es)
*
|
2013-04-19 |
2022-05-11 |
Univ South Florida |
Compuestos y composiciones de cocristal iónico de litio de anión orgánico
|
|
WO2014178040A1
(en)
|
2013-04-29 |
2014-11-06 |
Mapi Pharma Ltd. |
Co-crystals of dapagliflozin
|
|
KR102411227B1
(ko)
*
|
2013-10-17 |
2022-06-21 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
|
|
ES2788866T3
(es)
*
|
2013-12-13 |
2020-10-23 |
Conaris Res Institute Ag |
Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida para su uso en influir beneficiosamente en los niveles de lípidos en sangre mediante la modificación de la microbiota intestinal
|
|
SG11201507188QA
(en)
*
|
2014-03-24 |
2015-10-29 |
Kaohsiung Chang Gung Memorial Hospital |
Use of benzoic acid salt in the manufacture of a composition for preventing or treating dementia or mild cognitive impairment
|
|
CN103992320A
(zh)
*
|
2014-05-26 |
2014-08-20 |
南京工业大学 |
一种混悬结晶制备药物共晶的方法
|
|
PL3871515T3
(pl)
*
|
2014-05-27 |
2025-06-16 |
R. J. Reynolds Tobacco Company |
Sole nikotyny, ko-kryształy i kompleksy ko-kryształów soli
|
|
US9896429B2
(en)
*
|
2014-05-27 |
2018-02-20 |
R.J. Reynolds Tobacco Company |
Nicotine salts, co-crystals, and salt co-crystal complexes
|
|
WO2016081365A1
(en)
*
|
2014-11-19 |
2016-05-26 |
Rush University Medical Center |
Compositions and methods for treating lysosomal disorders
|
|
RU2582962C1
(ru)
|
2014-12-23 |
2016-04-27 |
Ольга Алексеевна Громова |
Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
|
|
KR102488927B1
(ko)
*
|
2016-06-13 |
2023-01-13 |
신유알엑스 인터내셔널 (타이완) 코포레이션 |
벤조산리튬의 공-결정 및 그의 용도
|
|
JP2019522067A
(ja)
|
2016-06-14 |
2019-08-08 |
エマージ リミテッド ライアビリティ カンパニー |
炭化器高温ガスの炭化水素再生利用
|
|
US10064833B2
(en)
*
|
2016-08-04 |
2018-09-04 |
Syneurx International (Taiwan) Corp. |
Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
|
|
US10336679B2
(en)
*
|
2016-10-24 |
2019-07-02 |
Syneurx International (Taiwan) Corp. |
Polymorphic forms of sodium benzoate and uses thereof
|
|
US9877942B1
(en)
*
|
2017-02-13 |
2018-01-30 |
Syneurx International (Taiwan) Corp. |
Co-crystals of substituted glycine and uses thereof
|
|
US20190076472A1
(en)
*
|
2017-09-14 |
2019-03-14 |
CT Development One, LLC |
Hyperammonemia therapy for children suffering from urea cycle disorders
|
|
US10098861B1
(en)
*
|
2017-10-24 |
2018-10-16 |
Syneurx International (Taiwan) Corp. |
Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
|